Back to User profile » Dr Baha Sharaf
Papers published by Dr Baha Sharaf:
Bridging Clinical Trials to Real-World Clinical Practice: TCHP Neoadjuvant Therapy Outcomes in HER2-Positive Breast Cancer
Sharaf B, Seif A, Bani Hani H, Alhasan M, Khader R, Al-Yag’oub M, Ghanem A, Bani Ata J, Ajlouni B, Jawarneh Q, Jaffal A, Tamimi F, Jehad S, Al-Abdallat H, Mahafdah O, Abdel-razeq H
Breast Cancer: Targets and Therapy 2026, 18:559555
Published Date: 9 April 2026
Enhancing Early Detection of Pancreatic Cancer in Genetically Predisposed Individuals: Integrating Advanced Imaging Modalities with Emerging Biomarkers and Liquid Biopsy
Abdel-Razeq R, Mansour A, Barbar M, Abu Shanap M, Sharaf B, Tamimi F, Mansour R, Muhanna A, Al-Othman Y, Hammad H, Shakhatreh M, Mahafdah S, Bani Hani H, Abdel-Razeq H
Biologics: Targets and Therapy 2025, 19:511-523
Published Date: 30 August 2025
Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer
Al-Batsh T, Abdel-Razeq N, Al-Masri Y, El-Khatib O, Sharaf B, Tamimi F, Abdel-Razeq H
Biologics: Targets and Therapy 2025, 19:97-111
Published Date: 13 March 2025
Dual Anti-HER2 Therapy Vs Trastuzumab Alone with Neoadjuvant Anthracycline and Taxane in HER2-Positive Early-Stage Breast Cancer: Real-World Insights
Sharaf B, Tamimi F, Al-Abdallat H, Khater S, Salama O, Zayed A, El Khatib O, Qaddoumi A, Horani M, AL-Masri Y, Asha W, Altalla’ B, Bani Hani H, Abdel-Razeq H
Biologics: Targets and Therapy 2025, 19:59-71
Published Date: 5 March 2025
Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country
Abdel-Razeq H, Sharaf B, Khater S, Baidoun HJ, Bani Hani H, Taqash A, El Khatib O, Edaily S, Abunasser M, Tamimi F, Al-Masri YN, Al-Batsh TMW, Zayed A, Ghatasheh T, Radaideh T
ImmunoTargets and Therapy 2024, 13:501-512
Published Date: 29 September 2024
Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib
Sharaf B, Abu-Fares H, Tamimi F, Al-Sawajneh S, Salama O, Daoud R, Alhajahjeh A, Al-Lababidi S, Abdel-Razeq H
Breast Cancer: Targets and Therapy 2023, 15:541-548
Published Date: 28 July 2023
Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer
Abdel-Razeq H, Abujamous L, Al-Azzam K, Abu-Fares H, Bani Hani H, Alkyam M, Sharaf B, Elemian S, Tamimi F, Abuhijla F, Edaily S, Salama O, Abdulelah H, Daoud R, Abubaker M, Al-Atary A
Breast Cancer: Targets and Therapy 2023, 15:1-10
Published Date: 13 January 2023
A Durable Response of Primary Advanced Colonic Plasmacytoma Using a Combination of Surgical Resection and Adjuvant Bortezomib: A Case Report and Literature Review
Alfar R, Kamal N, Abdel Razeq R, Omari Z, Bater R, Sharaf B
OncoTargets and Therapy 2022, 15:1347-1354
Published Date: 7 November 2022
Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
Abdel-Razeq H, Sharaf B
Drug Design, Development and Therapy 2022, 16:727-735
Published Date: 16 March 2022
Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
Abdel-Razeq H, Sharaf B, AlMasri R, Abdel-Razeq R, Tamimi F, Khader O, Salama O, Abunasser M, Edaily S, Abdulelah H
Cancer Management and Research 2022, 14:1033-1041
Published Date: 8 March 2022
Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review
Sharaf B, AlMasri R, Abdel-Razeq N, Salama O, Hamad I, Abunasser M, Abdel-Razeq H
Clinical, Cosmetic and Investigational Dermatology 2022, 15:5-10
Published Date: 5 January 2022